Superluminal secures $60M for Phase 1 of genetic obesity drug
A Boston biotech following in the footsteps of Rhythm Pharmaceuticals and others in the MC4R obesity field has raised $60 million to test its approach in Phase 1. Superluminal Medicines secured the Series B from ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.